1 week Ago By Defense World Staff
Geode Capital Management LLC raised its stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) by 63.0% in the 4th quarter, according to its most recent filing with the SEC.
The fund owned 221,257 shares of the company’s stock after purchasing an additional 85,557 shares during the period. Geode Capital Management LLC owned 0.87% of Cartesian Therapeutics worth $3,963,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd.
increased its position in shares of Cartesian Therapeutics by 22.8% in the 4th quarter. Mirae Asset Global Investments Co.
Ltd. now owns 4,562 shares of the company’s stock worth $82,000 after purchasing an additional 847 shares during the last quarter. Corebridge Financial Inc.
increased its position in shares of Cartesian Therapeutics by 32.6% in the 4th quarter. Corebridge Financial Inc.
now owns 5,122 shares of the company’s stock worth $92,000 after purchasing an additional 1,258 shares during the last quarter. China Universal Asset Management Co. Ltd.
bought a new stake in shares of Cartesian Therapeutics in the 4th quarter worth about $97,000. Rhumbline Advisers increased its position in shares of Cartesian Therapeutics by 10.0% in the 4th quarter.
Rhumbline Advisers now owns 10,201 shares of the company’s stock worth $183,000 after purchasing an additional 927 shares during the last quarter. Finally, Barclays PLC increased its position in shares of Cartesian Therapeutics by 208.6% in the 3rd quarter.
Barclays PLC now owns 11,611 shares of the company’s stock worth $188,000 after purchasing an additional 7,849 shares during the last quarter. Institutional investors own 86.95% of the company’s stock.
Cartesian Therapeutics Stock Down 1.8 %Shares of NASDAQ:RNAC opened at $11.83 on Monday.
Cartesian Therapeutics, Inc. has a fifty-two week low of $8.85 and a fifty-two week high of $41.
87. The company has a market cap of $306.48 million, a PE ratio of -0.
22 and a beta of 0.55. The firm has a 50-day simple moving average of $14.
52 and a 200 day simple moving average of $17.76. Analyst Ratings ChangesSeveral equities research analysts have recently weighed in on the stock.
HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Cartesian Therapeutics in a research report on Wednesday, April 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $41.
00 price objective on shares of Cartesian Therapeutics in a research report on Wednesday, April 9th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.
com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.67.View Our Latest Stock Report on RNACCartesian Therapeutics Company Profile (Free Report)Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases.
It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.Further ReadingFive stocks we like better than Cartesian TherapeuticsESG Stocks, What Investors Should KnowTexas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMost Volatile Stocks, What Investors Need to KnowO’Reilly Automotive: An Anytime Buy for Buy-and-Hold Investors3 Natural Gas Stocks That Offer Great Dividend YieldsChipotle Mexican Grill Serves Smoking Hot Entry Point in Q2.
